BPK-29 |
| رقم الكتالوجGC34502 |
BPK-29 عبارة عن يجند محدد يعطل تفاعلات بروتين NR0B1 لمستقبل نووي غير نمطي (مثل RBM45 و SNW1) عن طريق تعديل C274 تساهميًايضعف BPK-29 النمو المستقل عن الإرساء للخلايا السرطانية المتحولة KEAP1
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2143467-62-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BPK-29 is a covalent small molecule that disrupts NR0B1 complexes and impairs the anchorage-independent growth of KEAP1-mutant cancer cells[1].
BPK-29 substantially engages NR0B1 with good overall proteomic selectivity in KEAP1-mutant Non-Small Cell Lung Cancers[1].
[1]. Woodruff TM,et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol. 2008 Dec 15;181(12):8727-34.
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *